ADVERTISEMENT

Data

Strategic Surprises: The Drugs That Rewrote The Forecasts

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Consumers More Often Choosing Private Label First

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

Empty Promises: Five Drugs That Fell Short Of Their Sales Forecasts

Many assets underperform their pre-launch sales predictions, which can be disastrous to their developers and marketers. In this article, Scrip highlights several historic examples and the factors that influenced their poorer-than-expected performance.

Shigella Vaccine Pipeline And Why It Matters

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Oncology’s Most Eligible Unpartnered Assets

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

Another One Bites The Dust: FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?